The primary objective of the Biostatistics Core is to assist to the project investigators in the design, conduct, and analysis ofthe laboratory and clinical studies proposed in this program project grant (PPG). This core is led by Dr. Gary Rosner, Director of the Oncology Biostatistics and Bioinformatics Division. The Core focuses its efforts on assisting both the clinical and laboratory investigators in translating their pre-clinical studies into clinical studies by providing state-of-the-art experimental designs and analyses through statistical consultation and collaboration with respect to methodology, feasibility, safety monitoring, analysis, and reporting of clinical and laboratory studies. Additionally, Core members work closely with members of the Research Information Technology Systems (RITS) group, part of Oncology's Division of Biostatistics and Bioinformatics, to provide quality-controlled data in a systematic, efficient, and coordinated fashion so that accurate, complete, validated databases are available. This core has been and continues to be an integral part of the research accomplishments of the individual projects of this program project application

Public Health Relevance

The work ofthe Biostatistics Core helps ensure that laboratory and clinical studies are carried out efficiently with designs that will lead to valid scientific conclusions. This work is a critical part ofthe research seeking to improve outcomes for cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA015396-39
Application #
8727266
Study Section
Special Emphasis Panel (ZCA1-RPRB-B)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
39
Fiscal Year
2014
Total Cost
$150,409
Indirect Cost
$57,564
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Robinson, Tara M; O'Donnell, Paul V; Fuchs, Ephraim J et al. (2016) Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol 53:90-7
Kanakry, Christopher G; Fuchs, Ephraim J; Luznik, Leo (2016) Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol 13:10-24
Robinson, Tara M; Fuchs, Ephraim J (2016) Allogeneic stem cell transplantation for sickle cell disease. Curr Opin Hematol 23:524-529
DeZern, Amy E; Williams, Katherine; Zahurak, Marianna et al. (2016) Red blood cell transfusion triggers in acute leukemia: a randomized pilot study. Transfusion 56:1750-7
Gerber, Jonathan M; Zeidner, Joshua F; Morse, Sarah et al. (2016) Association of acute myeloid leukemia's most immature phenotype with risk groups and outcomes. Haematologica 101:607-16
Lombardi, Lindsey R; Kanakry, Christopher G; Zahurak, Marianna et al. (2016) Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leuk Lymphoma 57:666-75
Gondek, L P; Zheng, G; Ghiaur, G et al. (2016) Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. Leukemia 30:1916-20
Kanakry, Christopher G; Coffey, David G; Towlerton, Andrea M H et al. (2016) Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. JCI Insight 1:
Alonso, Salvador; Hernandez, Daniela; Chang, Yu-Ting et al. (2016) Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance. J Clin Invest 126:4460-4468
Kanakry, Christopher G; Fuchs, Ephraim J; Luznik, Leo (2016) Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol 13:132

Showing the most recent 10 out of 436 publications